ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2603

Real World Practice Based Clinical Study of Delayed-Release Prednisone Produces Comparable Results to a Controlled Clinical Trial: Morning Stiffness and Disease Measures in Moderate-Severe RA Patients Switched from Immediate-Release to Delayed Release-Prednisone

Ara H. Dikranian1, Rubaiya Mallay2, Mike Marshall3, Megan Francis-Sedlak3 and Robert J. Holt4,5, 1San Diego Arthritis Medical Clinic, San Diego, CA, 2Suncoast Internal Medicine Consultants and Largo Med Center, Largo, FL, 3Horizon Pharma USA, Inc, Lake Forest, IL, 4Medical Affairs, Horizon Pharma, Inc, Lake Forest, IL, 5College of Pharmacy, University of Illinois-Chicago, Vernon Hill, IL

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Disease Activity, outcomes, pain management, prednisolone, prednisone and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 15, 2016

Session Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with RA have previously demonstrated significant differences in morning stiffness (MS), a debilitating symptom of RA, and other disease measures with delayed release (DR)-prednisone versus immediate release (IR)-prednisone in a randomized trial and an open-label switch extension study (1,2). Previous randomized trials did not allow prednisone dose to be adjusted (1). We conducted a prospective open label switch study in the US to see if the results from controlled trials could be replicated in a real world clinical setting.

Methods: Twelve sites within the US enrolled 56 moderate-severe patients with RA into a 12 week study. At baseline patients were switched from IR- to DR-prednisone while maintaining other existing background therapies. MS severity (VAS1-100) the primary outcome, MS duration (minutes), swollen joint counts (SJC), DAS28, MDHAQ, RAPID3 and patient/physician global assessment (PGA/PhGA 10 cm VAS), among others, were measured (change from baseline). The overall group, those completing 10 wks, and those with >60 minutes of MS at baseline were analyzed, specifically. T-tests and Pearson’s Correlations were used for significance and associations.

Results: 52 patients had at least one follow-up visit and were similar to patients in the previous controlled trial with regard to baseline mean age (63), DAS28CRP (5.2) but had lower baseline morning stiffness (114 minutes) and shorter duration of RA (5yrs). From a mean starting dose of 6 mg, the dose of prednisone decreased by 13% after switch to DR-prednisone in those treated ≥10 wks while demonstrating significant reductions in SJC, DAS28CRP, PhGA, RAPID3 and MDHAQ pain (all p ≤ 0.04). Patients on treatment for ≥10 wks and who had baseline >60 min of MS produced similar results in SJC/PhGA as well as reductions in duration and severity of MS (both p<0.03, Figure 1). In the later analysis, MS severity (-20%) and duration (-34%) improvements were moderately correlated with each other (R2=0.43) and no other correlations were demonstrated.

Conclusion: Patients switched to DR-prednisone from IR-prednisone in this practice based study maintained or improved their outcomes across a variety of domains and the results were comparable to previous controlled trials in which patients completed at least 10 wks of therapy. Further, there was a reduction in total prednisone dose over the treatment period comparable to the 18% found in a previous analysis (3).  References:  (1)        Buttgereit, et al. Lancet 2008; 371: 205. (2)        Buttgereit, et al. Ann Rheum Dis 2010;69:1275. (3)        Cutolo, et al. Clin Exp Rheumatol 2013; 31:498.


Disclosure: A. H. Dikranian, Horizon Pharma USA, Inc, 2,Horizon Pharma USA, Inc, 8; R. Mallay, Horizon Pharma USA, Inc, 2,Abbvie, 8; M. Marshall, Horizon Pharma, 1,Horizon Pharma USA, Inc, 3; M. Francis-Sedlak, Horizon Pharma, 1,Horizon Pharma USA, Inc, 3; R. J. Holt, Horizon Pharma, 1,Horizon Pharma USA, Inc, 3.

To cite this abstract in AMA style:

Dikranian AH, Mallay R, Marshall M, Francis-Sedlak M, Holt RJ. Real World Practice Based Clinical Study of Delayed-Release Prednisone Produces Comparable Results to a Controlled Clinical Trial: Morning Stiffness and Disease Measures in Moderate-Severe RA Patients Switched from Immediate-Release to Delayed Release-Prednisone [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/real-world-practice-based-clinical-study-of-delayed-release-prednisone-produces-comparable-results-to-a-controlled-clinical-trial-morning-stiffness-and-disease-measures-in-moderate-severe-ra-patients/. Accessed January 21, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/real-world-practice-based-clinical-study-of-delayed-release-prednisone-produces-comparable-results-to-a-controlled-clinical-trial-morning-stiffness-and-disease-measures-in-moderate-severe-ra-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.